Cargando…
Efficacy of Hydroxy-L-proline (HYP) analogs in the treatment of primary hyperoxaluria in Drosophila Melanogaster
BACKGROUND: Substrate reduction therapy with analogs reduces the accumulation of substrates by inhibiting the metabolic pathways involved in their biosynthesis, providing new treatment options for patients with primary hyperoxalurias (PHs) that often progress to end-stage renal disease (ESRD). This...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6035412/ https://www.ncbi.nlm.nih.gov/pubmed/29980178 http://dx.doi.org/10.1186/s12882-018-0980-8 |
_version_ | 1783338047206588416 |
---|---|
author | Yang, Huan Male, Musa Li, Yang Wang, Ning Zhao, Chenming Jin, Shan Hu, Juncheng Chen, Zhiqiang Ye, Zhangqun Xu, Hua |
author_facet | Yang, Huan Male, Musa Li, Yang Wang, Ning Zhao, Chenming Jin, Shan Hu, Juncheng Chen, Zhiqiang Ye, Zhangqun Xu, Hua |
author_sort | Yang, Huan |
collection | PubMed |
description | BACKGROUND: Substrate reduction therapy with analogs reduces the accumulation of substrates by inhibiting the metabolic pathways involved in their biosynthesis, providing new treatment options for patients with primary hyperoxalurias (PHs) that often progress to end-stage renal disease (ESRD). This research aims to evaluate the inhibition efficacy of Hydroxy-L-proline (HYP) analogs against calcium oxalate (CaOx) crystal formation in the Drosophila Melanogaster (D. Melanogaster) by comparing them with Pyridoxine (Vitamin B6). METHODS: Three stocks of Drosophila Melanogaster (W(118), CG3926 RNAi, and Act5C-GAL4/CyO) were utilized. Two stocks (CG3926 RNAi and Act5C-GAL4 /CyO) were crossed to generate the Act5C > dAGXT RNAi recombinant line (F(1) generation) of D. Melanogaster which was used to compare the efficacy of Hydroxy-L-proline (HYP) analogs inhibiting CaOx crystal formation with Vitamin B(6) as the traditional therapy for primary hyperoxaluria. RESULTS: Nephrolithiasis model was successfully constructed by downregulating the function of the dAGXT gene in D. Melanogaster (P-Value = 0.0045). Furthermore, the efficacy of Hydroxy-L-proline (HYP) analogs against CaOx crystal formation was demonstrated in vivo using D. Melanogaster model; the results showed that these L-Proline analogs were better in inhibiting stone formation at very low concentrations than Vitamin B(6) (IC(50) = 0.6 and 1.8% for standard and dietary salt growth medium respectively) compared to N-acetyl-L-Hydroxyproline (IC(50) = 0.1% for both standard and dietary salt growth medium) and Baclofen (IC(50) = 0.06 and 0.1% for standard and dietary salt growth medium respectively). Analysis of variance (ANOVA) also showed that Hydroxy-L-proline (HYP) analogs were better alternatives for CaOx inhibition at very low concentration especially when both genetics and environmental factors are intertwined (p < 0.0008) for the dietary salt growth medium and (P < 0.063) for standard growth medium. CONCLUSION: Addition of Hydroxy-L-Proline analogs to growth medium resulted in the reduction of CaOx crystals formation. These analogs show promise as potential inhibitors for oxalate reduction in Primary Hyperoxaluria. |
format | Online Article Text |
id | pubmed-6035412 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-60354122018-07-09 Efficacy of Hydroxy-L-proline (HYP) analogs in the treatment of primary hyperoxaluria in Drosophila Melanogaster Yang, Huan Male, Musa Li, Yang Wang, Ning Zhao, Chenming Jin, Shan Hu, Juncheng Chen, Zhiqiang Ye, Zhangqun Xu, Hua BMC Nephrol Research Article BACKGROUND: Substrate reduction therapy with analogs reduces the accumulation of substrates by inhibiting the metabolic pathways involved in their biosynthesis, providing new treatment options for patients with primary hyperoxalurias (PHs) that often progress to end-stage renal disease (ESRD). This research aims to evaluate the inhibition efficacy of Hydroxy-L-proline (HYP) analogs against calcium oxalate (CaOx) crystal formation in the Drosophila Melanogaster (D. Melanogaster) by comparing them with Pyridoxine (Vitamin B6). METHODS: Three stocks of Drosophila Melanogaster (W(118), CG3926 RNAi, and Act5C-GAL4/CyO) were utilized. Two stocks (CG3926 RNAi and Act5C-GAL4 /CyO) were crossed to generate the Act5C > dAGXT RNAi recombinant line (F(1) generation) of D. Melanogaster which was used to compare the efficacy of Hydroxy-L-proline (HYP) analogs inhibiting CaOx crystal formation with Vitamin B(6) as the traditional therapy for primary hyperoxaluria. RESULTS: Nephrolithiasis model was successfully constructed by downregulating the function of the dAGXT gene in D. Melanogaster (P-Value = 0.0045). Furthermore, the efficacy of Hydroxy-L-proline (HYP) analogs against CaOx crystal formation was demonstrated in vivo using D. Melanogaster model; the results showed that these L-Proline analogs were better in inhibiting stone formation at very low concentrations than Vitamin B(6) (IC(50) = 0.6 and 1.8% for standard and dietary salt growth medium respectively) compared to N-acetyl-L-Hydroxyproline (IC(50) = 0.1% for both standard and dietary salt growth medium) and Baclofen (IC(50) = 0.06 and 0.1% for standard and dietary salt growth medium respectively). Analysis of variance (ANOVA) also showed that Hydroxy-L-proline (HYP) analogs were better alternatives for CaOx inhibition at very low concentration especially when both genetics and environmental factors are intertwined (p < 0.0008) for the dietary salt growth medium and (P < 0.063) for standard growth medium. CONCLUSION: Addition of Hydroxy-L-Proline analogs to growth medium resulted in the reduction of CaOx crystals formation. These analogs show promise as potential inhibitors for oxalate reduction in Primary Hyperoxaluria. BioMed Central 2018-07-06 /pmc/articles/PMC6035412/ /pubmed/29980178 http://dx.doi.org/10.1186/s12882-018-0980-8 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Yang, Huan Male, Musa Li, Yang Wang, Ning Zhao, Chenming Jin, Shan Hu, Juncheng Chen, Zhiqiang Ye, Zhangqun Xu, Hua Efficacy of Hydroxy-L-proline (HYP) analogs in the treatment of primary hyperoxaluria in Drosophila Melanogaster |
title | Efficacy of Hydroxy-L-proline (HYP) analogs in the treatment of primary hyperoxaluria in Drosophila Melanogaster |
title_full | Efficacy of Hydroxy-L-proline (HYP) analogs in the treatment of primary hyperoxaluria in Drosophila Melanogaster |
title_fullStr | Efficacy of Hydroxy-L-proline (HYP) analogs in the treatment of primary hyperoxaluria in Drosophila Melanogaster |
title_full_unstemmed | Efficacy of Hydroxy-L-proline (HYP) analogs in the treatment of primary hyperoxaluria in Drosophila Melanogaster |
title_short | Efficacy of Hydroxy-L-proline (HYP) analogs in the treatment of primary hyperoxaluria in Drosophila Melanogaster |
title_sort | efficacy of hydroxy-l-proline (hyp) analogs in the treatment of primary hyperoxaluria in drosophila melanogaster |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6035412/ https://www.ncbi.nlm.nih.gov/pubmed/29980178 http://dx.doi.org/10.1186/s12882-018-0980-8 |
work_keys_str_mv | AT yanghuan efficacyofhydroxylprolinehypanalogsinthetreatmentofprimaryhyperoxaluriaindrosophilamelanogaster AT malemusa efficacyofhydroxylprolinehypanalogsinthetreatmentofprimaryhyperoxaluriaindrosophilamelanogaster AT liyang efficacyofhydroxylprolinehypanalogsinthetreatmentofprimaryhyperoxaluriaindrosophilamelanogaster AT wangning efficacyofhydroxylprolinehypanalogsinthetreatmentofprimaryhyperoxaluriaindrosophilamelanogaster AT zhaochenming efficacyofhydroxylprolinehypanalogsinthetreatmentofprimaryhyperoxaluriaindrosophilamelanogaster AT jinshan efficacyofhydroxylprolinehypanalogsinthetreatmentofprimaryhyperoxaluriaindrosophilamelanogaster AT hujuncheng efficacyofhydroxylprolinehypanalogsinthetreatmentofprimaryhyperoxaluriaindrosophilamelanogaster AT chenzhiqiang efficacyofhydroxylprolinehypanalogsinthetreatmentofprimaryhyperoxaluriaindrosophilamelanogaster AT yezhangqun efficacyofhydroxylprolinehypanalogsinthetreatmentofprimaryhyperoxaluriaindrosophilamelanogaster AT xuhua efficacyofhydroxylprolinehypanalogsinthetreatmentofprimaryhyperoxaluriaindrosophilamelanogaster |